1. Home
  2. ALKT vs NVAX Comparison

ALKT vs NVAX Comparison

Compare ALKT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$15.18

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.49

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
NVAX
Founded
2007
1987
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
ALKT
NVAX
Price
$15.18
$8.49
Analyst Decision
Buy
Hold
Analyst Count
7
9
Target Price
$28.57
$11.33
AVG Volume (30 Days)
2.0M
4.4M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
$152,159,000.00
$1,123,479,000.00
Revenue This Year
$21.85
N/A
Revenue Next Year
$16.90
N/A
P/E Ratio
N/A
$3.47
Revenue Growth
35.68
64.69
52 Week Low
$14.11
$5.01
52 Week High
$31.18
$11.85

Technical Indicators

Market Signals
Indicator
ALKT
NVAX
Relative Strength Index (RSI) 33.70 38.12
Support Level $14.11 $8.01
Resistance Level $23.80 $9.05
Average True Range (ATR) 0.82 0.54
MACD -0.15 -0.23
Stochastic Oscillator 0.61 1.81

Price Performance

Historical Comparison
ALKT
NVAX

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: